Sentynl secures option for US alvelestat rights in Phase III-ready AATD lung disease programme

The agreement gives Zydus subsidiary Sentynl Therapeutics an option for exclusive US commercial and global manufacturing rights to Mereo BioPharma’s oral neutrophil elastase inhibitor, with Mereo leading preparations for pivotal development.

Zydus Lifesciences subsidiary Sentynl Therapeutics has entered an option and licence agreement with Mereo BioPharma covering US commercial and global manufacturing rights to alvelestat, a Phase III-ready oral neutrophil elastase inhibitor for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo will receive an undisclosed non-refundable option fee and, if Sentynl exercises its option, up to $40 million in upfront and R&D payments through NDA filing, with Mereo also eligible for tiered double-digit royalties on US net sales if the drug is approved.

Field	Content
Alert Type	Deal
Companies	Sentynl Therapeutics, a wholly owned subsidiary of Zydus Lifesciences; Mereo BioPharma
Deal Type	Option and licensing agreement
Asset or Company	Alvelestat (MPH-966)
Therapy Area(s)	Respiratory; Rare disease; Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)
Technology or Modality	Oral small-molecule neutrophil elastase inhibitor
Deal Value	Mereo will receive an undisclosed non-refundable option fee. If Sentynl exercises the option, Mereo is eligible for up to $40 million in upfront and R&D payments through NDA filing, plus tiered double-digit royalties on US net sales if alvelestat is approved. The $40 million is contingent on option exercise and subsequent development and should not be treated as guaranteed consideration. (Economic Times Pharma)
Development Stage	Phase III-ready
Geography	United States commercial rights; global manufacturing rights
What Happened	Sentynl Therapeutics has entered an option and licence agreement with Mereo BioPharma for alvelestat. The agreement gives Sentynl an option to acquire exclusive US commercial rights and global manufacturing rights, while Mereo will lead the global Phase III study and regulatory interactions through completion during the option period. The companies will collaborate on manufacturing and refinement of the Phase III design, with Sentynl expected to sponsor the late-stage programme if it exercises the option. Mereo has previously indicated that a pivotal study could enrol approximately 220 patients over an 18-month treatment period. (Economic Times Pharma)
Why It Matters	The agreement provides Mereo with a potential route to finance and advance alvelestat into pivotal development while giving Sentynl access to a late-stage rare respiratory disease programme without immediately committing to a full licence. Alvelestat targets neutrophil elastase in AATD-LD, and Mereo has already aligned with the FDA and EMA on independent primary endpoints intended to support potential US and European regulatory submissions. (Mereo BioPharma)
Supporting Context	AATD-LD is a rare genetic condition caused by alpha-1 antitrypsin deficiency that can lead to progressive lung damage. Alvelestat has received FDA Orphan Drug and Fast Track designations and European orphan designation; Mereo has evaluated the drug across two Phase II studies and completed feasibility work in preparation for pivotal development. (Mereo BioPharma)
Strategic Rationale	Sentynl gains the option to add a Phase III-ready rare respiratory asset to its portfolio together with global manufacturing rights, while limiting its initial commitment during further development planning. Mereo gains a potential development and commercial partner while retaining responsibility for advancing the global Phase III programme during the option period.
Potential Impact	If the option is exercised and Phase III development is successful, the partnership could advance alvelestat towards regulatory submissions in AATD-LD and give Sentynl exclusive US commercial rights. Any clinical or commercial impact remains dependent on successful pivotal development and regulatory approval.
Key Takeaway	The option structure gives Sentynl access to a Phase III-ready rare respiratory programme while providing Mereo with a potential partner to advance alvelestat towards pivotal development and US commercialisation.
What to Watch	Exercise of Sentynl’s option, finalisation of the Phase III design and initiation of the pivotal programme, which Sentynl expects could begin in early 2027 if the option is exercised. (Economic Times Pharma)
Primary Source	Mereo BioPharma / Zydus Lifesciences-Sentynl Therapeutics agreement announcement
Relevant Date	12 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com